BioCryst launch­es aware­ness cam­paign around man­age­ment of rare vas­cu­lar dis­ease

While hered­i­tary an­gioede­ma (HAE) is rare, treat­ment op­tions for the con­di­tion have be­come much more com­mon. So BioCryst Phar­ma­ceu­ti­cals is tak­ing a new an­gle in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER